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The cytokine and cell adhesion protein osteopontin (OPN)
has been implicated in tumor progression in tumors of var-
ious origins including breast, prostate, lung, colon, and
head and neck tumors (Coppola et al, 2004). OPN protein
levels in the tumors were highest in tumors of gastrointes-
tinal, genitourinary, and gynecological origin, and lowest in
tumors of the breast, skin, brain, and salivary gland. Wheth-
er OPN is expressed by the tumor cells, peritumoral inflam-
matory cells, or both, its expression correlated positively
with tumor stage, dramatically so in colon adenocarcino-
mas. A partial explanation for this may be that OPN can
stimulate angiogenesis, possibly by recruiting pro-
angiogenic monocytes (Hirama et al, 2003; Leali et al,
2003). Now in this issue of JID, Youwen Zhou, Gang Li, and
colleagues working at the University of British Columbia,
Canada, describe a microarray study of gene expression in
developing metastatic human melanomas, revealing that
OPN expression increased significantly when the mela-
nomas acquired invasive, metastatic capabilities.
OPN is a secreted phosphoprotein found in all body flu-
ids and mineralized tissues (Sodek et al, 2000). Because it is
a ligand for several widely expressed integrins including
avb1, 3, or 5, and a4, 8, or 9b1, and certain CD44 variants, it
is capable of activating signal transduction pathways con-
trolled by these receptors (Denhardt et al, 2001a). OPN
binds strongly to bone mineral, via both its multiple
phosphoserine residues and its aspartic acid-rich domain,
thereby supporting the attachment of bone cells to bone
mineral via the above-mentioned receptors. Its role as a
cytokine is less evident, but obviously important, particu-
larly during the inflammatory response where its expression
is increased and it attracts monocytes/macrophages to
sites of injury and infection, regulates NFkB and iNOS ex-
pression, and alters the Th1/Th2 ratio (Denhardt et al,
2001a, b).
A number of studies suggest that OPN signaling facili-
tates the survival of cells subjected to various stressful sit-
uations, hypoxia or growth factor-deprivation for example
(Denhardt et al, 2003). Importantly, OPN-deficient (knock-
out) mice are defective in bone remodeling and resistant to
the progression of autoimmune disease (Denhardt et al,
2001a, b). Both phenotypes may result from the ability of
OPN to inhibit the apoptotic response of bone or immune
cells that would otherwise die. Similarly, it is possible that
OPN promotes metastasis by prolonging the survival of
cancer cells. Consistent with such a model are the results
reported by Ohyama et al (2004) that B16F10 melanoma
cells injected into ablated bone marrow cavities formed 5-
fold fewer tumors in OPN-deficient mice than in control
mice. It appears that the presence of exogenous host OPN
facilitated the attachment, survival, and/or growth of the
melanoma cells. Presumably, high-level expression of OPN
by the tumor cells would serve a similar purpose.
Because OPN expression is increased by activation of
Ras, protein kinase C, or PI3-K/Akt, it is not surprising to find
elevated OPN levels in tumors where the signal transduction
pathways involving these molecules are upregulated (Den-
hardt et al, 2001a, b, 2003), e.g., in the hypoxic, low-pH
environment of tumors (Le et al, 2003). That OPN actually
stimulates tumor progression and metastasis has been doc-
umented in studies reporting that targeted downregulation
(by anti-sense RNA or small inhibitory RNA (siRNA)) or up-
regulation (by direct transfection of an OPN-expressing con-
struct) of OPN expression caused a decrease or increase,
respectively, of the tumorigenic/metastatic efficiency (Den-
hardt et al, 2001a, b; Adwan et al, 2004; Rittling and Cham-
bers, 2004).
Studies on the hepatocyte growth factor/scatter factor
(HGF/SCF)-Met receptor tyrosine kinase axis have shed
light on a second mechanism by which OPN can stimulate
metastasis. Tuck et al (2000) described experiments show-
ing that OPN-induced migration of mammary epithelial cells
involved activation of Met, possibly indirectly through avb3
rather than through HGF/SCF. Medico et al (2001) found that
HGF not only stimulated OPN expression in mouse liver
progenitor cells but also promoted cell adhesion to OPN via
CD44, the hyaluronan receptor; they suggested that OPN
was an autocrine mediator of HGF/SCF-induced invasive
growth. Recio and Merlino (2003) described a feedback
loop in which CD44v6, an OPN receptor, and Met were up-
regulated by HGF in melanoma cells, perhaps to compen-
sate for depletion of the Met receptor resulting from HGF
signaling. Ariztia et al (2003), using a mouse liver epithelial
line, showed that HGF-induced tumorigenesis and experi-
mental metastasis formation were both attenuated by anti-
sense OPN-mediated inhibition of OPN expression. They
also showed that enhanced OPN expression alone did not
confer tumorigenicity of metastatic ability on these cells.
The mRNA encoding CD63, which encodes a melanoma-
associated antigen (ME491) that belongs to the tetraspan
family of receptors, was also upregulated by HGF. As HGF/Abbreviations: HGF, hepatocyte growth factor; OPN, osteopontin
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SCF-Met have been implicated in melanoma development
(Li et al, 2001; Walker and Hayward, 2002), it would appear
that contributing to melanoma progression is a complicated
positive feedback loop involving Met and OPN along with its
integrin and CD44 receptors.
Melanocytes, from which melanomas originate, are nor-
mally restricted to the basal layer of the epidermis, in part
because dermal collagen induces their apoptosis possibly
because of their inability to adhere to native collagen Type I
(Geissinger et al, 2002). Therefore, as a first step, in mela-
noma progression, melanocytes must acquire the ability
to invade and survive in the dermal layer, events in part
regulated by basic fibroblast growth factor (bFGF) (Alanko
et al, 1999). Geissinger et al (2002) reported that OPN,
which can be induced by bFGF (FGF2), inhibited apoptosis
of melanocytes grown in dermal collagen by a process de-
pendent upon OPN binding to the avb3 integrin. Petitclerc
et al (1999) reported that avb3 was required for survival and
growth of melanoma tumors in full-thickness human skin.
Although the authors suggested that denatured proteoly-
tically cleaved collagen was the ligand responsible, a role
for OPN was not excluded. The ability of soluble OPN to
bind to several receptors typically engaged by molecules
constituting the extracellular matrix (ECM), and thereby
mimicking ECM signaling, may be a unique feature of OPN
(Denhardt et al, 2001b).
Matrix metalloproteinases (MMP) and serine proteinases
(e.g., urokinase-type plasminogen activator) are important
weapons in the metastatic cell arsenal; they can degrade
both cell adhesion molecules and ECM molecules, enabling
tumor cells both to escape from a tumor and to invade
adjacent tissues. OPN regulates MMP activities in various
ways. It can bind to proMMP-9 and promote its activation
(Fedarko et al, 2004), and it can induce NFkB-mediated
proMMP-2 and -9 activation through an IkBa/IKK signaling
pathway (Rangaswami et al, 2004). These proteinases have
the potential to cleave cell adhesion molecules, thereby fa-
cilitating the release of tumor cells from the growing tumor.
Autocrine HGF signaling was reported by Li et al (2001) to
downregulate levels of the melanoma adhesion proteins E-
cadherin and Desmoglein I, possibly in part by proteolysis,
thereby enabling tumor cell dissemination. OPN can also
increase uPA mRNA levels and urokinase activity in medium
conditioned by breast cancer cells, enhancing their inva-
siveness (Tuck et al, 1999). Thus in two quite different ways
(inhibiting tumor cell apoptosis, stimulating tumor cell, or
endothelial cell invasiveness) OPN accelerates tumor
progression.
Zhou et al (2005) report in their high-density DNA micro-
array analysis that among 14 (of 14,000) genes whose tran-
scripts were highly (20-fold) overexpressed in metastatic
melanoma nodules, OPN was the most abundant. OPN
upregulation in metastatic nodules and melanoma cell lines
was confirmed at the mRNA level by quantitative RT-PCR
and also by western analysis of OPN protein levels in the
melanoma lines, all of which were derived from metastatic
melanomas and were highly metastatic. Suppression of
OPN expression in one of these lines (KZ-28) by means of a
siRNA reduced the cell number measured 2 days later,
consistent with the possibility that OPN either stimulated
proliferation or inhibited apoptosis of this cell line in culture.
Although not tested, results in other systems imply that the
tumorigenicity and experimental metastatic efficiency of
these cells will be reduced in comparison with the parent
cells. This study thus adds skin cancer (melanomas) to the
set of cancers (above) in which OPN expression not only
increases as the tumors become progressively more ma-
lignant but also contributes actively in one or more ways to
tumor invasion and metastasis (Furger et al, 2001; Weber,
2001). Zhou et al (2005) suggest that OPN might serve as a
therapeutic target for melanoma; however, the authors also
note that in contrast to many other cancers, no correlation
between OPN expression and metastasis or patient survival
has been reported so far.
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